Neonatal transfusion-transmitted hepatitis C virus infection following a pre-seroconversion window-phase donation in sweden

Scandinavian Journal of Infectious Diseases

Volumn 45, Issue 10, 2013, Pages 796-799

  Waldenström, Jesper ^a   Konar, Jan ^b   Ekermo, Bengt ^c   Norder, Helene ^a   Lagging, Martin ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Core antigen; Cost effectiveness; Hepatitis C virus; NAT; Transfusion transmission

Indexed keywords

HEPATITIS C ANTIGEN; HEPATITIS C CORE ANTIGEN; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; BLOOD DONOR; CASE REPORT; ERYTHROCYTE CONCENTRATE; GREAT VESSELS TRANSPOSITION; HEPATITIS C; HUMAN; IMMUNOASSAY; INFANT; LIMIT OF DETECTION; MALE; NEEDLESTICK INJURY; POLYMERASE CHAIN REACTION; RECIPIENT; RETROSPECTIVE STUDY; SCREENING; SEROCONVERSION; SWEDEN;

BLOOD TRANSFUSION; HEPATITIS C; HEPATITIS C ANTIGENS; HUMANS; INFANT, NEWBORN; MALE; PLASMA; RNA, VIRAL; SWEDEN; VIRAL CORE PROTEINS;

EID: 84884379613     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2013.797601     Document Type: Article

References (16)

1. Schuttler CG, Caspari G, Jursch CA, Willems WR, Gerlich WH, Schaefer S . Hepatitis C virus transmission by a blood donation negative in nucleic acid amplifi cation tests for viral RNA . Lancet 2000; 355 : 41-2 .
2. Busch MP, Kleinman SH, Jackson B, Stramer SL, Hewlett I, Preston S . Committee report. Nucleic acid amplifi cation testing of blood donors for transfusion-transmitted infectious diseases: report of the Interorganizational Task Force on Nucleic Acid Amplifi cation Testing of Blood Donors . Transfusion 2000; 40 : 143-59 .
3. Coste J, Reesink HW, Engelfriet CP, Laperche S, Brown S, Busch MP, et al . Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003 . Vox Sang 2005; 88 : 289-303 .
4. Harritshoj LH, Dickmeiss E, Hansen MB, Ullum H, Jorgensen LB, Gerstoft J . Transfusion-transmitted human immunodefi ciency virus infection by a Danish blood donor with a very low viral load in the preseroconversion window phase . Transfusion 2008; 48 : 2026-8 .
5. Loe Wiig F. T o fi kk blod fra Hepatitt C-smittet giver. Available at: http://www.nito.no/Fagmiljoer/Bioingeniorfagliginstitutt/ Bioingenioren/Alle- Bioingeniorene/Bioingenioren- 2011/Bioingenioren-10-20111/To-fikk-blod-fra- Hepatitt- C-smittet-giver-/ (accessed 7 October 2011).
6. Duberg A, Janzon R, Back E, Ekdahl K, Blaxhult A . T he epidemiology of hepatitis C virus infection in Sweden . Euro Surveill 2008 ; 13 . pii: 18882 .
7. Lagging M, Duberg AS, Wejstal R, Weiland O, Lindh M, Aleman S, et al . Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations . Scand J Infect Dis 2012; 44 : 502-21 .
8. Davidson T, Ekermo B, Gaines H, Lesko B, Akerlind B. T he cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodefi ciency virus among blood donors in Sweden . Transfusion 2011; 51 : 421-9 .
9. Widell A, Elmud H, Persson M H, Jonsson M. T ransmission of hepatitis C via both erythrocyte and platelet transfusions from a single donor in serological window-phase of hepatitis C . Vox Sang 1996; 71 : 55-7 .
10. Transfusionsmedicin SFF. B lodverksamheten i Sverige 2011: omfattning, kvalitet och s ä kerhet . Available at: http://www. transfusion.se/wp- content/uploads/2012/08/Blodverksamheten- i-Sverige-2011.pdf (accessed 27 July 2012).
11. Socialstyrelsen. S enaste version av SOSFS 2009:28 Socialstyrelsens f ö reskrifter om blodverksamhet . Available at: http://www.socialstyrelsen. se/sosfs/2009-28/ (accessed 1 April 2010).
12. Weusten J, Vermeulen M, van Drimmelen H, Lelie N . Refi nement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms . Transfusion 2011; 51 : 203-15 .
13. European Pharmacopoeia 5.0. 5 th ed . European Directorate for the Quality of Medicines (EDQM), Council of Europe: Strasbourg; 2005. http://lib.njutcm.edu.cn/yaodian/ep/EP5. 0/16-monographs/monographs-d-k/ Human%20plasma%20 for%20fractionation.pdf
14. Alsio A, Jannesson A, Langeland N, Pedersen C, Farkkila M, Buhl MR, et al . Early quantifi cation of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection . Eur J Clin Microbiol Infect Dis 2012; 31 : 1631-5 .
15. Park Y, Lee J H, Kim B S, Kim D Y, Han K H, Kim H S. N ew automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantifi cation . J Clin Microbiol 2010; 48 : 2253-6 .
16. Medici MC, Furlini G, Rodella A, Fuertes A, Monachetti A, Calderaro A, et al . Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay . J Clin Virol 2011; 51 : 264-9